Page 18 - Array Biopharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

[co-author: Sarah Taheny] The European Commission (EC) has published new guidance on the application of Article 22 of the European Merger Regulation (EUMR) which will allow for the EC and Member States to refer transactions that do not meet existing EC or national jurisdictional thresholds for EC review. On March 26, 2021, the EC published its Staff Working Document (Working Document) on the Evaluation of Procedural and Jurisdictional Aspects of EU Merger Control, 1 the latest step in its evaluation of proposed reforms of the EUMR. 2 The EC also launched an accompanying impact assessment desi...

Tyler Jacks, Ph.D., after 19 years. The director role will be taken over by Matthew Vander Heiden, M.D., Ph.D., a professor of biology at MIT and a medical oncologist at Dana-Farber Cancer Institute. He became a member of the Koch Institute in 2010 and took over for Jacks on Thursday, MIT said. Jacks will continue to lead the Bridge Project, which unites bioegnineers, cancer scientists and clinical oncologists from the Koch Institute and the Dana-Farber/Harvard Cancer Center. > Atara Biotherapeutics ushered Amie Krause into the role of senior vice president and chief people officer Apri...

Published: Apr 09, 2021 By Alex Keown Atara Biotherapeutics – Amie Krause was named Senior Vice President and Chief People Officer at Atara Biotherapeutics. In this role, Krause will be tasked with building a company culture that “rewards” values through actions and results. Prior to her tenure with Atara, Krause held several HR leadership positions at Amgen, including her role as Global HR Lead, Organizational Effectiveness during which she served as the human resources lead for Amgen’s global commercial operations covering the Americas, Europe, Asia, and the Middle East. Ps...

Cogent Biosciences Announces Creation of Cogent Research Team Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21 News provided by Share this article Share this article BOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNew...

BOULDER — Cogent Biosciences Inc. (Nasdaq: COGT) hired former Array Biopharma research leader John Robinson as its chief scientific officer, and said it will house a team of researchers in Boulder. In a statement, Cambridge, Massachusetts-based Cogent said it plans to initially hire eight researchers in a rented laboratory space in north Boulder but eventually plans to build its own dedicated facility to house up to 50 researchers. Robinson will lead the new team from Boulder after spending time as a vice president with pharmaceutical giant Pfizer Inc. (NYSE: PFE), which he joined after it ...